Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single-Centre Study Evaluating the Safety, Tolerability and Pharmacokinetics of Single and Multiple Escalating Doses of Intravenous Formulation of Solithromycin (CEM-101) In Healthy Adult Subjects.

Next Previous
Search
Trial Profile

A Phase 1, Single-Centre Study Evaluating the Safety, Tolerability and Pharmacokinetics of Single and Multiple Escalating Doses of Intravenous Formulation of Solithromycin (CEM-101) In Healthy Adult Subjects.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Solithromycin (Primary)
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 05 Jun 2017 Results of the single ascending dose portion (n=42), presented at the ASM Microbe 2017.
    • 09 Aug 2012 Cempra expects to complete this trial in the second half of 2012.
    • 10 May 2011 Results presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases and the 27th International Congress of Chemotherapy.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top